Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance

BACKGROUND: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substantially improved patients’ prognosis, drug resistance remains one of the major...

Descripción completa

Detalles Bibliográficos
Autores principales: Klümper, Theresa, Bruckmueller, Henrike, Diewock, Tobias, Kaehler, Meike, Haenisch, Sierk, Pott, Christiane, Bruhn, Oliver, Cascorbi, Ingolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519530/
https://www.ncbi.nlm.nih.gov/pubmed/32999756
http://dx.doi.org/10.1186/s40164-020-00183-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519530/
https://www.ncbi.nlm.nih.gov/pubmed/32999756
http://dx.doi.org/10.1186/s40164-020-00183-1

Ejemplares similares